231 related articles for article (PubMed ID: 35216966)
1. Immune effector cell-associated neurotoxicity syndrome: A therapeutic approach in the critically ill.
Suarez Montero JC; Caballero Gonzalez AC; Martín Aguilar L; Mancebo Cortés J
Med Intensiva (Engl Ed); 2022 Apr; 46(4):201-212. PubMed ID: 35216966
[TBL] [Abstract][Full Text] [Related]
2. Immune effector cell-associated neurotoxicity syndrome: A therapeutic approach in the critically ill.
Suarez Montero JC; Caballero Gonzalez AC; Martín Aguilar L; Mancebo Cortés J
Med Intensiva (Engl Ed); 2020 Aug; ():. PubMed ID: 32873409
[TBL] [Abstract][Full Text] [Related]
3. Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study.
Gutierrez C; Brown ART; May HP; Beitinjaneh A; Stephens RS; Rajendram P; Nates JL; Pastores SM; Dharshan A; de Moraes AG; Hensley MK; Feng L; Brudno JN; Athale J; Ghosh M; Kochenderfer JN; Arias AS; Lin Y; McEvoy C; Mead E; Westin J; Kostelecky N; Mian A; Herr MM
Crit Care Med; 2022 Jan; 50(1):81-92. PubMed ID: 34259446
[TBL] [Abstract][Full Text] [Related]
4. Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy.
Sterner RC; Sterner RM
Front Immunol; 2022; 13():879608. PubMed ID: 36081506
[TBL] [Abstract][Full Text] [Related]
5. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
[TBL] [Abstract][Full Text] [Related]
6. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study.
Azoulay É; Castro P; Maamar A; Metaxa V; de Moraes AG; Voigt L; Wallet F; Klouche K; Picard M; Moreau AS; Van De Louw A; Seguin A; Mokart D; Chawla S; Leroy J; Böll B; Issa N; Levy B; Hemelaar P; Fernandez S; Munshi L; Bauer P; Schellongowski P; Joannidis M; Moreno-Gonzalez G; Galstian G; Darmon M; Valade S;
Lancet Haematol; 2021 May; 8(5):e355-e364. PubMed ID: 33894170
[TBL] [Abstract][Full Text] [Related]
7. A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy.
Ruff MW; Siegler EL; Kenderian SS
Neurol Clin; 2020 Nov; 38(4):953-963. PubMed ID: 33040871
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment.
Gu T; Hu K; Si X; Hu Y; Huang H
WIREs Mech Dis; 2022 Nov; 14(6):e1576. PubMed ID: 35871757
[TBL] [Abstract][Full Text] [Related]
9. Neurological adverse effects of chimeric antigen receptor T-cell therapy.
Saleki K; Mohamadi MH; Alijanizadeh P; Rezaei N
Expert Rev Clin Immunol; 2023; 19(11):1361-1383. PubMed ID: 37578341
[TBL] [Abstract][Full Text] [Related]
10. Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies.
Siegler EL; Kenderian SS
Front Immunol; 2020; 11():1973. PubMed ID: 32983132
[TBL] [Abstract][Full Text] [Related]
11. Severe persistent neurotoxicity associated with CAR T therapy in children.
Andrew EC; Hughes D; Gilsenan M; Mignone C; Khaw SL; Wang SS
Br J Haematol; 2023 Nov; 203(4):651-655. PubMed ID: 37528536
[TBL] [Abstract][Full Text] [Related]
12. Toxicities following CAR-T therapy for hematological malignancies.
Hernani R; Benzaquén A; Solano C
Cancer Treat Rev; 2022 Dec; 111():102479. PubMed ID: 36308910
[TBL] [Abstract][Full Text] [Related]
13. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.
Freyer CW; Porter DL
J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies.
Xiao X; Huang S; Chen S; Wang Y; Sun Q; Xu X; Li Y
J Exp Clin Cancer Res; 2021 Nov; 40(1):367. PubMed ID: 34794490
[TBL] [Abstract][Full Text] [Related]
15. Neurotoxicity-CAR T-cell therapy: what the neurologist needs to know.
Neill L; Rees J; Roddie C
Pract Neurol; 2020 Aug; 20(4):285-293. PubMed ID: 32503897
[TBL] [Abstract][Full Text] [Related]
16. Reactions Related to CAR-T Cell Therapy.
Miao L; Zhang Z; Ren Z; Li Y
Front Immunol; 2021; 12():663201. PubMed ID: 33995389
[TBL] [Abstract][Full Text] [Related]
17. Neuroimaging findings in immune effector cell associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy.
Lapidus AH; Anderson MA; Harrison SJ; Dickinson M; Kalincik T; Lasocki A
Leuk Lymphoma; 2022 Oct; 63(10):2364-2374. PubMed ID: 35570737
[TBL] [Abstract][Full Text] [Related]
18. Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with immune effector cell-associated neurotoxicity syndrome (ICANS) following CD19 CAR T-cell therapy for mantle cell lymphoma.
Nie EH; Ahmadian SS; Bharadwaj SN; Acosta-Alvarez L; Threlkeld ZD; Frank MJ; Miklos DB; Monje M; Scott BJ; Vogel H
J Neuropathol Exp Neurol; 2023 Jan; 82(2):160-168. PubMed ID: 36592076
[TBL] [Abstract][Full Text] [Related]
19. Management of the Critically Ill Adult Chimeric Antigen Receptor-T Cell Therapy Patient: A Critical Care Perspective.
Gutierrez C; McEvoy C; Mead E; Stephens RS; Munshi L; Detsky ME; Pastores SM; Nates JL
Crit Care Med; 2018 Sep; 46(9):1402-1410. PubMed ID: 29939878
[TBL] [Abstract][Full Text] [Related]
20. Neurotoxicity Biology and Management.
Danish H; Santomasso BD
Cancer J; 2021 Mar-Apr 01; 27(2):126-133. PubMed ID: 33750072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
